This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2004;292:2824-2825.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Researchers hope that the emergence of numerous biomarkers for cardiovascular disease in recent years will enable physicians to better assign risk and treat patients.

A number of patients with coronary heart disease do not exhibit traditional risk factors such as hypertension, elevated cholesterol levels, obesity, and smoking. Conversely, many individuals who do have such risk factors do not have cardiovascular disease. A nuanced understanding of biomarkers, researchers note, could increase the accuracy of risk assessment.

Biomarkers—data taken from blood or urine samples—emerged as tools for researchers to understand the pathobiology of atherothrombosis; perhaps the most common screenings are those used for cholesterol. So far, biomarkers are used mostly at the point of care for patients with acute conditions, said David Moliterno, MD, professor and chief of cardiology at the University of Kentucky in Lexington. For example, troponin measurements can show whether someone has had a high-risk myocardial infarction, . . . [Full Text of this Article]

C-REACTIVE PROTEIN



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Metabolic Syndrome (Emperor) Wears No Clothes
Kahn
Diabetes Care 2006;29:1693-1696.
FULL TEXT